Progyny stock has delivered a steep 49.9% decline over the past five years, yet the broader valuation checks suggest the shares may now be closer to fair value than the long term chart alone implies.

• Over five years, shareholders have seen Progyny fall 49.9%, which sets a cautious backdrop for any case that the current price offers value.
• The valuation outlook can benefit if Progyny continues to convert revenue into reliable cash flows, while any slowdown in employer adoption of its fertility benefits or pressure on margins may limit how much investors are willing to pay.
• On Simply Wall St's checks, Progyny looks inexpensive on most measures, with the stock screening as attractive on 5 of 6 valuation tests. You can review those tests in more detail here.

The issue now is whether Progyny's recent share price around US$25.96 already reflects this stronger set of valuation checks or still leaves room for a re rating.

Where Does Progyny Sit on Earnings?

The P/E ratio suits Progyny because the company is already generating earnings that investors can compare directly with peers. Progyny currently trades on a P/E of about 25.3x, which is almost identical to the Healthcare industry average of 25.3x and below the peer group average of 39.2x. That means the stock is not priced at a premium to the broad sector even though peers on average are carrying higher earnings multiples.

Simply Wall St's fair P/E for Progyny is about 27.4x, which is only slightly above the current market multiple. The gap between the two is small, so on this framework the share price lines up closely with what the model suggests for a company with Progyny's profile. If you put weight on earnings based valuation, the stock neither screens as clearly cheap nor stretched.

On the P/E test, Progyny looks roughly fairly valued compared with both its tailored fair multiple and the wider Healthcare sector.

The Progyny Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Progyny pick up where the valuation puzzle leaves off. They spell out the specific growth, margin and earnings paths that would need to play out for Progyny's stock to be worth materially more or less than today. They sit on the Community page so you can see those assumptions laid out and monitor over time whether the real world is tracking the future that each valuation figure relies on.

One of the top community narratives on Progyny: 23% undervalued

"Positive momentum in client retention and upselling, with renewals featuring either sustained or expanded benefits even in a cautious macro environment, enhances revenue predictability and underpins steady earnings growth..."

Do you think there's more to the story for Progyny? Head over to our Community to see what others are saying!

The Bottom Line

Progyny now trades on earnings multiples that line up closely with both its Healthcare peers and its own tailored fair P/E, so the easy valuation argument is largely behind you. The stock screens as inexpensive across most checks, yet not to an extent that clearly challenges the current market view. What really matters from here is whether Progyny can keep turning employer demand for fertility benefits into resilient margins and cash generation. The central debate is whether that strength supports a steadier multiple over time or whether any slowdown in adoption or margin pressure leaves the shares stuck where they are.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.